Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Профилактика рака шейки матки: методы ранней диагностики и новые скрининговые технологии (Клиническая лекция)
Профилактика рака шейки матки: методы ранней диагностики и новые скрининговые технологии (Клиническая лекция)
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Прилепская В.Н., Кондриков Н.И., Бебнева Т.Н. Патология шейки матки. Диагностические возможности цитологического скрининга. Акуш. и гин. 1999; 3: 45–50.
2. Кулаков В.И., Аполихина И.А., Прилепская В.Н., Сухих Г.Т. Современные подходы к диагностике папилломавирусной инфекции гениталий женщин и их значение для скрининга рака шейки матки. Гинекология. 2000; 1 (2): 4–8.
3. Козаченко В.П. Рак шейки матки. Совр. онкол. 2001; 2 (2): 2 4.
4. Роговская С.И., Прилепская В.Н. Профилактика папилломавирусной инфекции и рака шейки матки. Гинекология. 2005; 1 (7): 22–6.
5. Бебнева Т.Н., Прилепская В.Н. Папилломавирусная инфекция и патология шейки матки. Гинекология. 2001; 3 (3): 77–81.
6. Acladius NN, Sutton C, Mandal D et al. Persistent human papillomavirus infection and smoking increase risk of failure of treatment of cervical intraepithelial neoplasia (CIN). Int J Cancer 2002; 98 (3): 435–9.
7. Agnantis NJ, Sotiriadis A, Paraskevaidis E. The current status of HPV DNA testing. Eur J Gynaecol Oncol 2003; 24: 351–603.
8. Boyle P, Autier P, Bartelink H et al. European code against cancer and scientific justification: third version (2003). Ann Oncol 2003; 14: 973–1005.
9. Davey E, Barratt A, Irwig et al. Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: a systematic review. Lancet 2006; 376: 122–32.
10. Franco El, Harper DM. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 2005; 23: 2388–94.
11. Frazer Ian H., Cox J. Thomas, Mayeaux Edward John et al. Advances in Prevention of Cervical Cancer and Other Human Papillomavirus-Related Diseases. The Pediatric Infectious Diseases Journal, Vol 25, No 2, Suppl. February 2006.
12. Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent LI virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757–65.
13. Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4,5 years of a bivalent LI virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised controlled trial. Lancet 2006.
14. Klaes R et al. Overexpression of p16ink4a as a specific marker for displastic and neoplastic cells in cervical cancer. Iny J Cancer 2001; 92:276–84.
15. Nuovo J, Melnikow J, Howell LP. New tests for cervical cancer screening. Am Fam Physician 2001; 64: L780–6.
16. Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004; 364: 249–56.
17. Sankaranarayanan R, Gaffikin L, Jacob M et al. A critical assessment of screening methods for cervical neoplasia. Int J Gynecol Obstet 2005; 89: S4–l2.
18. Saslow D, Runowicz CD, Solomon D et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002; 52: 342–62. http://CAonline.AmCancerSoc. org. Accessed 19 June 2006.
19. Solomon D, Davey D, Kurman R et al. The 2001 Bethesda System. Terminology for reporting results of cervical cytology. JAMA 2002; 287 (16): 2114–8.
20. Steenbergen RDM, C Meijer,P Snijers. Molecular Markers for Cervical Cancer. In book Mosonego.... 2006.
21. World Health Organization (WHO). Comprehensive Cervical Cancer Control. A guide to essential practice. Geneva: WHO 2006.
22. Villa LL, Costa RLR, Petta CA et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 virus-like particle vaccine through 5 years of follow-up. British Journal of Cancer (2006) 96, 1459–1466.
2. Кулаков В.И., Аполихина И.А., Прилепская В.Н., Сухих Г.Т. Современные подходы к диагностике папилломавирусной инфекции гениталий женщин и их значение для скрининга рака шейки матки. Гинекология. 2000; 1 (2): 4–8.
3. Козаченко В.П. Рак шейки матки. Совр. онкол. 2001; 2 (2): 2 4.
4. Роговская С.И., Прилепская В.Н. Профилактика папилломавирусной инфекции и рака шейки матки. Гинекология. 2005; 1 (7): 22–6.
5. Бебнева Т.Н., Прилепская В.Н. Папилломавирусная инфекция и патология шейки матки. Гинекология. 2001; 3 (3): 77–81.
6. Acladius NN, Sutton C, Mandal D et al. Persistent human papillomavirus infection and smoking increase risk of failure of treatment of cervical intraepithelial neoplasia (CIN). Int J Cancer 2002; 98 (3): 435–9.
7. Agnantis NJ, Sotiriadis A, Paraskevaidis E. The current status of HPV DNA testing. Eur J Gynaecol Oncol 2003; 24: 351–603.
8. Boyle P, Autier P, Bartelink H et al. European code against cancer and scientific justification: third version (2003). Ann Oncol 2003; 14: 973–1005.
9. Davey E, Barratt A, Irwig et al. Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: a systematic review. Lancet 2006; 376: 122–32.
10. Franco El, Harper DM. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 2005; 23: 2388–94.
11. Frazer Ian H., Cox J. Thomas, Mayeaux Edward John et al. Advances in Prevention of Cervical Cancer and Other Human Papillomavirus-Related Diseases. The Pediatric Infectious Diseases Journal, Vol 25, No 2, Suppl. February 2006.
12. Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent LI virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757–65.
13. Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4,5 years of a bivalent LI virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised controlled trial. Lancet 2006.
14. Klaes R et al. Overexpression of p16ink4a as a specific marker for displastic and neoplastic cells in cervical cancer. Iny J Cancer 2001; 92:276–84.
15. Nuovo J, Melnikow J, Howell LP. New tests for cervical cancer screening. Am Fam Physician 2001; 64: L780–6.
16. Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004; 364: 249–56.
17. Sankaranarayanan R, Gaffikin L, Jacob M et al. A critical assessment of screening methods for cervical neoplasia. Int J Gynecol Obstet 2005; 89: S4–l2.
18. Saslow D, Runowicz CD, Solomon D et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002; 52: 342–62. http://CAonline.AmCancerSoc. org. Accessed 19 June 2006.
19. Solomon D, Davey D, Kurman R et al. The 2001 Bethesda System. Terminology for reporting results of cervical cytology. JAMA 2002; 287 (16): 2114–8.
20. Steenbergen RDM, C Meijer,P Snijers. Molecular Markers for Cervical Cancer. In book Mosonego.... 2006.
21. World Health Organization (WHO). Comprehensive Cervical Cancer Control. A guide to essential practice. Geneva: WHO 2006.
22. Villa LL, Costa RLR, Petta CA et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 virus-like particle vaccine through 5 years of follow-up. British Journal of Cancer (2006) 96, 1459–1466.
Авторы
В.Н.Прилепская
ФГУ Научный центр акушерства, гинекологии и перинатологии Федерального агентства по высокотехнологичной
медицинской помощи, Москва
ФГУ Научный центр акушерства, гинекологии и перинатологии Федерального агентства по высокотехнологичной
медицинской помощи, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.